The role of biomarkers is increasingly recognized in heart failure (HF) management, for
diagnosis, prognostication, and screening of high-risk patients. Beyond natriuretic peptides …

Publications regarding the potential clinical utility of biomarker testing in the management of
heart failure have been exponentially increasing over the last decade. The majority of non …

The increasing use of cardiac biomarkers in the diagnosis and management of heart failure
(HF) has led to their inclusion in clinical practice guidelines. Studies have demonstrated that …

Cardiac biomarkers are very important in diagnosis, risk stratification, and management of
patients with heart failure. Although not meeting all criteria for an ideal biomarker, natriuretic …

Heart failure is a complex disease in which a careful clinical examination and the
measurement of cardiac function may not always be sufficient for making a correct …

New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

The management of heart failure patients (diagnosis, treatment monitoring, assessment of
prognosis) crucially depends on the accuracy of the tools used for patient evaluation. While …

A profusion of circulating candidate biomarkers in heart failure is currently being
investigated. Although all will advance our insight into the pathophysiology of heart failure …

Biomarkers play an important role in heart failure, but there remain unanswered questions
regarding optimization of their use. They should be used as an adjunct to, not replacement …

The pathophysiology of heart failure is complex, and the list of biomarkers representing
distinct pathophysiologic pathways is growing rapidly. Other articles in this issue of the Heart …